Oramed Pharmaceuticals Inc.
NASDAQ:ORMPBiotechnology
Healthcare
$3.69 +0.79%
+$0.03 today
- Market cap
- $160.46M
- Beta
- 1.24
- P/E (TTM)
- 1.4
- EPS (TTM)
- $2.70
- Dividend yield
- 6.54%
52W Low $1.98High $5.01
Volume 0.27M
Average 0.16M
Income Statement
Follow revenue through to earnings.
Revenue
$2.00M
FY 2025 · Annual
Operating Income
-$15.09M
FY 2025 · Annual
Net Income
$64.05M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Aug 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 2.7M | 2.7M | 1.34M | 0 | 2M |
| Cost of Revenue | 0 | 0 | 0 | 193K | 1.99M |
| Gross Profit | 2.7M | 2.7M | 1.34M | (193K) | 13K |
| Gross Margin | 100.0% | 100.0% | 100.0% | — | 0.7% |
| Research & Development | 20.99M | 27.64M | 8.97M | 6.32M | 6.38M |
| Selling, General & Admin | 5.94M | 15.66M | 8.14M | 6.46M | 8.72M |
| Operating Expenses | 26.93M | 43.3M | 17.11M | 12.78M | 15.1M |
| Depreciation & Amortization | 77K | 3.62M | 196K | 193K | 121K |
| EBITDA | (25.04M) | (36.98M) | 7.32M | (14.87M) | 75.45M |
| EBITDA Margin | -926.3% | -1368.0% | 546.3% | — | 3772.2% |
| Operating Income | (24.22M) | (40.6M) | (15.77M) | (12.78M) | (15.09M) |
| Operating Margin | -896.2% | -1502.0% | -1176.8% | — | -754.4% |
| Interest Income | 347K | 3.57M | 8.03M | 0 | 2.37M |
| Interest Expense | 6K | 0 | 3.58M | 853K | 0 |
| Other Income / Expenses | 893K | 2.93M | 20.86M | (3.14M) | 90.41M |
| Income Before Tax | (22.99M) | (37.66M) | 5.09M | (15.92M) | 75.32M |
| Pre-Tax Margin | -850.5% | -1393.4% | 379.7% | — | 3766.2% |
| Income Tax Expense | (2.88M) | 100K | 0 | 3.18M | 11.31M |
| Net Income | (22.24M) | (37.76M) | 5.53M | (19.1M) | 64.05M |
| Net Margin | -822.7% | -1397.1% | 412.3% | — | 3202.5% |
| EPS (Basic) | (0.78) | (0.97) | 0.14 | (0.47) | 1.53 |
| EPS (Diluted) | (0.78) | (0.97) | 0.14 | (0.47) | 1.50 |
| 28.47M | 39M | 40.32M | 40.83M | 41.4M | |
| 28.47M | 39M | 40.57M | 40.83M | 42.42M |
ORMP Earnings Waterfall · TTM
NASDAQ:ORMP · Revenue to Net Income
Key Ratios
EPS$2.58
Gross Margin0.0%
Net Margin0.0%
P/E Ratio1.5
P/S Ratio0.0
Analysis
$0 of revenue converted into $110.0M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $2.58, tying the income statement back to per-share earnings.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 4 | Statement of changes in beneficial ownership | Nov 13, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 13, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 13, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 13, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 13, 2026 |
How much revenue does ORMP generate?
Oramed Pharmaceuticals Inc. (ORMP) reported $2.00M of revenue in fiscal 2025.
Is ORMP profitable?
Oramed Pharmaceuticals Inc. (ORMP) reported $64.05M of net income, with a net margin of 3202.5%.
Continue the stock analysis
Jump to another research area for this company.